Subscribe To
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors Initial KVA12123 monotherapy clinical safety, pharmacokinetic, receptor occupancy and biomarker data to be presented at SITC 2023 Expected Cash Runway into early 2025 SEATTLE, Nov. […] The post Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update appeared...
Read More
Posted: Nov 3 2023, 20:01
Author Name: forextv
Views: 112325